Antimicrobial resistance in Salmonella spp. is of grave concern, more so in quinolone-resistant and extended-spectrum b-lactamase (ESBL)-producing isolates that cause complicated infections. The MIC of azithromycin, ciprofloxacin, cefixime, cefepime, ceftriaxone, gatifloxacin, imipenem, levofloxacin, meropenem and ofloxacin (E-test strip) and tigecycline and faropenem (agar dilution) against 210 Salmonella spp. was determined. MIC 90 (defined as the antimicrobial concentration that inhibited growth of 90 % of the strains) of the carbapenems (imipenem and meropenem) for Salmonella Typhi and Salmonella Paratyphi A was 0.064 mg ml "1 . MIC 90 of faropenem was 0.25 mg ml "1 for S. Typhi, S. Paratyphi A and Salmonella Typhimurium. The MIC 90 of azithromycin for all Salmonella spp. ranged from 8 to 16 mg ml "1
INTRODUCTION
Nalidixic acid-resistant (NAR) Salmonella causing enteric fever are now also found to be ciprofloxacin resistant; this has necessitated the search for novel antimicrobials. Options available for treatment of enteric fever include newer quinolones, extended-spectrum cephalosporins and azithromycin (Cooke et al., 2006; Kownhar et al., 2007; Parry et al., 2007) . A large number of current and previous studies question the efficacy of newer quinolones in treating enteric fever caused by ciprofloxacin-resistant Salmonella (Harish et al., 2006; Joshi & Amarnath, 2007) . A rise in the MIC of third and fourth generation cephalosporins for Salmonella spp. has been observed recently (Capoor et al., 2006; Saha et al., 1999) .
A number of studies have observed a rise in the MIC of azithromycin. Despite its intracellular concentration and clinical efficacy, it cannot be used in routine treatment of enteric fever due to a lack of large-scale in vivo and in vitro studies (Capoor et al., 2007; Frenck et al., 2004; Girgis et al., 1999; Parry et al., 2007) .
The roles of newer classes of antimicrobials, such as glycylcyclines and carbapenems, against salmonellae need to be elucidated. Tigecycline is a glycylcycline (tetracycline analogue), it inhibits protein synthesis and evades efflux and target-mediated resistance seen against classical tetracyclines (Livermore, 2005; Fritsche et al., 2005) . The carbapenems are a class of b-lactam antibiotics with broadspectrum activity and are stable to hydrolysis by extendedspectrum b-lactamase (ESBL)-producing isolates (Sorbera et al., 2002) . Though the use of carbapenems is not recommended (CLSI, 2006) , it may become crucial, especially when treating ESBL-producing salmonellae causing enteric fever (Pokharel et al., 2006) . Moreover, with an increase in the incidence of unusual and complicated paratyphoid fever (Harish et al., 2006) and non-typhoidal salmonellae causing septicaemia (Egorova et al., 2007; Sun et al., 2005) , the development of newer broad-spectrum antimicrobials needs to be explored.
The current study was carried out to assess the MIC of the currently available and novel antimicrobials for salmonellae isolates from a region that is endemic for NAR strains and is currently facing ciprofloxacin resistance in salmonellae that cause enteric fever.
METHODS
The current study was conducted on Salmonella isolates recovered from enteric fever and septicaemia cases at Vardhman Mahaveer Medical College, Safdarjung Hospital (a tertiary care centre) and Majeedia Hospital (a private referral hospital) in New Delhi, India, over a period of 2 years (2006) (2007) . Blood for culture was collected prior to initiation of antimicrobial therapy using aseptic procedures, and was processed using standard microbiological protocols (Old, 1996) . Salmonella spp. were identified using standard biochemical tests (Old, 1996) and confirmed by detection with specific antisera (Central Research Institute, Kasauli, India).
A total of 479 isolates of Salmonella spp. were recovered from 38 282 blood cultures. Of these, 210 isolates were randomly selected for the study. Antimicrobial susceptibility testing of the isolates was carried out by the standard Kirby Bauer disk-diffusion method using Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2006 ). Isolates resistant to ampicillin, chloramphenicol and co-trimoxazole were defined as multidrug-resistant (MDR).
The MIC of azithromycin, ciprofloxacin, cefixime, cefepime, ceftriaxone, gatifloxacin, imipenem, levofloxacin, meropenem and ofloxacin for the 210 Salmonella isolates was determined by using Etest strips (AB Biodisk). The results were interpreted according to the CLSI guidelines (CLSI, 2006) . The MIC of tigecycline and faropenem (Ranbaxy laboratories, Gurgaon, India) for Salmonella isolates was determined by agar dilution on cation-adjusted Mueller-Hinton agar. Isolates with intermediate levels of resistance were included in the percentage of resistant organisms for final analysis. Escherichia coli ATCC 25922 was used as a control strain.
The breakpoint MIC levels for azithromycin, tigecycline and faropenem for isolates of Salmonella spp. have not been determined. However, for the current study, breakpoints for faropenem and azithromycin that were determined in previous in vitro studies were used (Piddock et al., 2003; Girgis et al., 1999) . For tigecycline, the Food and Drug Administration (FDA)-approved susceptibility test result interpretative criteria were used (Brown & Traczewski, 2007 The Salmonella isolates were screened for the presence of ESBL production by using the double disk diffusion method using ceftazidime (30 mg ml 21 ), cefoperazone (75 mg ml
21
), ceftriaxone (30 mg ml 21 ) and cefotaxime (30 mg ml
). Presence of ESBL was confirmed by using combination E-test strips containing cefotaxime and cefotaxime-clavulanic acid or cefepime and cefepime-clavulanic acid. A threefold or more fall in MIC in the presence of clavulanic acid was considered to be indicative of ESBL production.
RESULTS AND DISCUSSION
Of the 210 isolates recovered from blood cultures from suspected cases of enteric fever and septicaemia, Salmonella Typhi was the predominant serotype (149, 70.95 %), followed by Salmonella Paratyphi A (43, 20.47 %) and Salmonella Typhimurium (17, 8.1 %); one Salmonella Enteritidis isolate was identified. Multidrug resistance was seen in S. Typhi (6, 4 %), S. Paratyphi A (2, 4.6 %) and S. Typhimurium For the quinolones that were tested (ciprofloxacin, gatifloxacin, levofloxacin and ofloxacin), the antimicrobial levofloxacin (Le), ofloxacin (Of) and gatifloxacin (Ga), ¡2, 4, ¢8; imipenem (I) and meropenem (M), ¡4, 8, ¢16; faropenem (F) and azithromycin (Az), breakpoints analysed by prior in vitro studies indicated ¢325resistant (Piddock et al., 2003; Girgis et al., 1999) ; ceftriaxone (Ci), ¡8, 16-32, ¢64; cefixime (Cfx), ¡1, 2, ¢4; cefepime (Cpm), ¡8, 16, ¢32; tigecycline (Ti), ¡2, 4, ¢8. ) for S. Typhi. The MIC 90 of gatifloxacin for S. Paratyphi A was 2 mg ml 21 and was 1 mg ml 21 for other quinolones. Nonetheless, the antimicrobial concentration that inhibited growth of 50 % of the strains (MIC 50 ) of all quinolones for S. Typhi and S. Paratyphi A was 0.5 mg ml 21 and 0.5-1 mg ml
21
, respectively. In contrast, the MIC 50 and MIC 90 of all quinolones for S. Typhimurium were in the susceptible range. The resistant MICs seen for the majority of isolates in this study have also been observed in prior studies (Capoor et al., 2007; Cooke et al., 2006; Joshi & Amarnath, 2007; Kownhar et al., 2007) . Thus, the higher (resistant) MICs suggest that quinolones should be withdrawn from use in treatment of enteric fever and that their use should be restricted to septicaemia cases caused by other salmonellae. Quinolones should not be used in the therapy of patients infected with NAR isolates as these are associated with therapeutic failures, despite their decreased susceptibility (0.125-1 mg ml
) to ciprofloxacin and other quinolones (Capoor et al., 2006; Cooke et al., 2006; Kownhar et al., 2007) .
Cefepime had the lowest MIC 90 , at 0.25 mg ml 21 , for S. Typhi and S. Paratyphi A. This may be attributed to its parenteral route of administration, making it less effective than cefixime. Only a single isolate of S. Typhi was an ESBL producer and had a high MIC for cephalosporins (resistant phenotype). Until now, there have been few reports of ESBL producers in S. Typhi and S. Paratyphi A strains (Pokharel et al., 2006) . Overuse of cephalosporins in ciprofloxacin-resistant salmonellae causing enteric fever has selected for the production of ESBL-producing isolates. In stark contrast to ESBL production in S. Typhi, there are many reports of ESBL-producing S. Typhimurium in the literature (Egorova et al., 2007; Weill et al., 2006; AitMhand et al., 2002; Otkun et al., 2001) . This was also observed in our study, as 94.1 % of the S. Typhimurium isolates were ESBL producers. Frequent production of ESBL in S. Typhimurium is attributable to plasmidmediated class A ESBLs belonging to the TEM, SHV and CTX-M or PER CMY family (Weill et al., 2006) . As this type of resistance is commonly transferred by these isolates to other bacteria, the transfer to S. Typhi and S. Paratyphi A is a major risk.
The MIC 90 values of azithromycin for S. Typhi, S. Paratyphi A and S. Typhimurium were 8, 16 and 8 mg ml
, respectively. In a prior study on ciprofloxacin-resistant S. Typhi and S. Paratyphi A (Capoor et al., 2007) , the MIC 90 was 24 mg ml 21 . The high MIC 90 may have been due to the fact that this study was performed using ciprofloxacin-resistant isolates only. In contrast, isolates were randomly selected in the current study and there was no selection bias for quinolone-resistant isolates. A rise in the MIC of azithromycin was predicted (Girgis et al., 1999; Butler et al., 1999; Frenck et al., 2004; Capoor et al., 2007) because of its injudicious out-patient use. Nonetheless, keeping in mind its intracellular concentration, large-scale randomized clinical trials are warranted to determine the correlation between in vivo and in vitro studies.
In this study, the MIC 90 of the penems (imipenem and meropenem) for S. Typhi and S. Paratyphi A (0.064 mg ml
) was lower compared with that for S. Typhimurium (0.125 mg ml
). Overall, faropenem had a high MIC 90 (0.25 mg ml 21 ) for S. Typhi, S. Paratyphi A and S. Typhimurium compared with the other penems. Previous reports (Piddock et al., 2003; Sun et al., 2005) also observed that faropenem was less active than imipenem, where the MIC 90 for salmonellae was reported as 0.5-1 mg ml
. Penems are a class of b-lactam antibiotic which possess potent broad-spectrum activity and are extremely stable against ESBLs (Sorbera et al., 2002) .
Against our collection of isolates, tigecycline was very potent, inhibiting 97.3 % of S. Typhi, as well as 100 % of S. Paratyphi A and S. Enteritidis. This is in agreement with the European committee on antimicrobial susceptibility testing (EUCAST) data and a prior study conducted on a large group of Salmonella isolates [European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee, 2006; Morosini et al., 2006; Brown & Traczewski, 2007] . Only 55.5 % of S. Typhimurium isolates were in the sensitive range for tigecycline. It should be noted, however, that the MIC 90 for S. Typhimurium isolates (4 mg ml
) was higher than that for the other species tested, and it was at the breakpoint of susceptibility, as approved by the FDA. The findings of our study are consistent with those of EUCAST.
In vivo and in vitro studies have demonstrated that acquired resistance to tigecycline is associated with upregulation of a chromosomally mediated efflux pump (Livermore, 2005; Brown & Traczewski, 2007 ) . Tigecycline lacks crossresistance with other compounds and it could aid in the therapy of MDR salmonelloses. Resistance to or a high MIC of tigecycline was rare in our collection of Salmonella isolates showing resistance to or high MIC of quinolones. Furthermore, tigecycline was also active against ceftriaxone-resistant Salmonella isolates. Nevertheless, systematic large-scale in vivo studies are needed to assess the relative merits of tigecycline versus other antimicrobials in the treatment of these infections. Unfortunately, owing to presence of the b-lactam ring, strains resistant to the penems show cross-resistance to other antimicrobials.
Enteric fever caused by ciprofloxacin-resistant salmonellae is found uniquely in countries of the Indian subcontinent. In India, this may be attributed to misuse of ciprofloxacin due to administration via the oral route, affordability, over-the-counter availability and its spurious quality (Capoor et al., 2006) . The observations of this study imply that tigecycline and the penems represent a reserve of antimicrobials that have therapeutic potential for the treatment of ESBL-producing MDR salmonellae in the future. Clinical efficacy trials are warranted to reach a conclusion in this regard.
